Cannabinoids for Medical Use
University Hospitals Bristol NHS Foundation Trust · National Institute for Health Research · +8 more institutions
Abstract
Cannabis and cannabinoid drugs are widely used to treat disease or alleviate symptoms, but their efficacy for specific indications is not clear.
To conduct a systematic review of the benefits and adverse events (AEs) of cannabinoids. DATA SOURCES: Twenty-eight databases from inception to April 2015. STUDY SELECTION: Randomized clinical trials of cannabinoids for the following indications: nausea and vomiting due to chemotherapy, appetite stimulation in HIV/AIDS, chronic pain, spasticity due to multiple sclerosis or paraplegia, depression, anxiety disorder, sleep disorder, psychosis, glaucoma, or Tourette syndrome. DATA EXTRACTION AND SYNTHESIS: Study quality was assessed using the Cochrane risk of bias tool. All review stages were conducted independently by 2 reviewers. Where possible, data were pooled using random-effects meta-analysis. MAIN OUTCOMES AND MEASURES: Patient-relevant/disease-specific outcomes, activities of daily living, quality of life, global impression of change, and AEs.
Citation impact
- FWCI
- 145.32
- Percentile
- 100%
- References
- 138
Authors
13- PWPenny WhitingCorresponding
University Hospitals Bristol NHS Foundation Trust, National Institute for Health Research, University of Bristol, Kleijnen Systematic Reviews (United Kingdom)
- RWRobert Wolff
Kleijnen Systematic Reviews (United Kingdom)
- SDSohan Deshpande
Kleijnen Systematic Reviews (United Kingdom)
- MDMarcello Di Nisio
Amsterdam UMC Location University of Amsterdam
- SDSteven Duffy
Kleijnen Systematic Reviews (United Kingdom)
Topics & keywords
- Medicine
- Nausea
- Adverse effect
- Clinical trial
- Pregabalin
- Placebo
- Clinical Global Impression
- Depression (economics)
- Good health and well-being